

Obesity, Hyperfiltration, and Early Kidney Damage: A New Formula for the Estimation of Creatinine Clearance

Alessio Basolo,^{1,*}  Guido Salvetti,^{1,*} Domenico Giannese,² Susanna Bechi Genzano,¹ Giovanni Ceccarini,¹ Riccardo Giannini,³ Gianluca Sotgia,⁴ Paola Fierabracci,¹ Paolo Piaggi,⁵ and Ferruccio Santini¹

¹Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Pisa 56124, Italy

²Department of Clinical and Experimental Medicine, University of Pisa, Pisa 56124, Italy

³Department of Surgical, Medical, Molecular Pathology and Critical Area, University Hospital of Pisa, Pisa 56124, Italy

⁴Consorzio Metis, University Hospital of Pisa, Pisa 56124, Italy

⁵Department of Information Engineering, University of Pisa, Pisa 56100, Italy

Correspondence: Alessio Basolo, MD, PhD, Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Pisa 56124, Italy.

Email: alessio.basolo@med.unipi.it

*These authors contributed equally to the study.

Abstract

Context: Glomerular hyperfiltration may represent a direct pathogenetic link between obesity and kidney disease. The most widely used methods to estimate creatine clearance such as Cockcroft–Gault (CG), Modification of Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) have not been validated in subjects with obesity.

Objective: The performance of prediction formulas was compared with measured creatinine clearance (mCrCl) in subjects with obesity.

Methods: The study population included 342 patients with obesity (mean BMI 47.6 kg/m²) without primary kidney disease. A urine collection was performed over 24 hours for measurement of CrCl.

Results: mCrCl increased with body weight. The CG formula showed an overestimation at high CrCl, whereas an underestimation resulted from CKD-EPI and MDRD. To improve the accuracy of estimated CrCl (eCrCl), a new CG-based formula was developed:

$53 + 0.7 \times (140 - \text{Age}) \times \text{Weight} / (96 \times \text{SCr}) \times (0.85 \text{ if female})$

A cut-off point for BMI of 32 kg/m² was identified, at which the new formula may be applied to improve eCrCl.

Conclusion: In patients with obesity the glomerular filtration rate increases with body weight, and it is associated with the presence of albuminuria, suggesting an early kidney injury. We propose a novel formula that improves the accuracy of eCrCl to avoid missed diagnoses of hyperfiltration in patients with obesity.

Key Words: obesity, creatinine clearance, hyperfiltration, kidney damage

Abbreviations: BMI, body mass index; BSA, body surface area; CG, Cockcroft–Gault; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; GFR, glomerular filtration rate; mCrCl, measured creatinine clearance; MDRD, Modification of Diet in Renal Disease; SCr, serum creatinine.

Obesity has become a worldwide epidemic and it is associated with various comorbidities including type 2 diabetes, cardiovascular and chronic kidney diseases (CKDs) (1, 2). A high body mass index (BMI) is a strong risk factor for new-onset CKD (3). The glomerular filtration rate (GFR) is defined as the volume of glomerular filtration per unit time and it is the gold standard for the measurement of kidney function. An increased total GFR, named glomerular hyperfiltration, is observed in a state of obesity (4) and it may represent a direct pathogenetic link between obesity and kidney disease, possibly leading to renal function loss in the long-term, if left untreated (3, 5). Several mechanisms have been proposed to explain the pathogenesis of hyperfiltration, including hemodynamic changes associated with a disequilibrium of vasoactive molecules that regulate the tone of afferent and efferent arterioles in the glomeruli, increased renal blood flow (4, 5), sodium reabsorption (6, 7), activation of

renin–angiotensin–aldosterone system (8), secretion of hormones from the adipose tissue (9, 10), inflammation (11), and oxidative stress (12). Hyperfiltration is considered a precursor of intraglomerular hypertension that might induce albuminuria, an early sign of kidney injury (13). In case of delayed detection, the presence of albumin in the urine may evolve to a state of glomerulomegaly (14), glomerulosclerosis (15), and possibly to the development or progression of nephropathy in the long-term (13). In clinical practice, it is crucial to evaluate the kidney function with the aim to identify the presence of kidney damage. The most accurate and precise measurement of GFR (inulin clearance) is methodologically difficult in clinical settings (high cost, complex protocol, and time-consuming). Although not very accurate and/or inconvenient for clinicians and patients, other methods (creatinine clearance, urea, cystatin C, and radioisotopic methods) have been used in clinical or research settings to estimate the renal

function (16). Thus, prediction formulas using serum creatinine levels including Cockcroft–Gault (CG) (17), Modification of Diet in Renal Disease (MDRD) (18), and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) (19) are currently the most widely used methods in routine clinical practice as surrogates for the estimation of GFR. Several studies suggest that estimated CrCl (eCrCl) using CG, MDRD and CKD-EPI formulas is not accurate compared with the measurement of CrCl in subjects with obesity (20–22). The lack of accuracy of eCrCl in obesity may lead to missed diagnoses of hyperfiltration/early kidney disease that requires a prompt treatment to avoid a progression to CKD and kidney failure over time. The aim of this study was to evaluate the kidney function by comparing the eCrCl using the prediction formulas (CG, CKD-EPI, and MDRD) with measured CrCl (mCrCl) by 24-hour urine collection in a large population of subjects with obesity. We have elaborated a new prediction formula for eCrCl in this population at high risk for CKD.

Materials and Methods

Study Populations

The study population included 342 patients with obesity (BMI 47.6 ± 8.9 kg/m² ranging from 30 to 96 kg/m², age 49.2 ± 12.5 years) evaluated at the Obesity and Lipodystrophy Center, Endocrinology Unit, University Hospital of Pisa, Italy. At the time of the visit, 4% had class I obesity, 13% had class II obesity, and 83% had class III obesity (BMI > 40 kg/m²). Patients with history of type 2 diabetes for more than 5 years and/or under insulin therapy and those with primary kidney disease and/or with mCrCl <60 mL/min were excluded, as well as patients with urine creatinine <950 mg/24 hours (suggestive of incomplete urine collection that may underestimate CrCl).

All patients underwent measurement of body weight, height, systolic blood pressure, and diastolic blood pressure. Body weight, in light clothing, was measured (to the nearest 0.1 kg) with a digital electronic scale. Standing height, with no shoes, was measured (to the nearest 1 cm) using stadiometer. BMI was calculated as the weight in kilograms divided by the square of the height in meters. Overweight and obesity were classified according to conventional definitions (23). Systolic blood pressure and diastolic blood pressure were measured with an electronic device and the average of 2 measurements in the sitting position with an interval of 2 minutes with an appropriate cuff. Patients were classified as hypertensive when their blood pressure was >140/90 mmHg or when they were on antihypertensive treatment at the time of blood pressure measurement.

Blood samples were drawn in the fasting state in the morning for the measurement of serum glucose, insulin and creatinine. Urine collection was performed over 24 hours for calculation of CrCl as follows:

$$\text{creatinine clearance} = (24\text{-hour urinary creatinine} \\ \times \text{urinary volume}) / \text{serum creatinine}$$

eCrCl was calculated by the main formulas (Table 1) as previously described (17–19). It has to be noted that CKD-EPI and MDRD formulas, at variance with CG, do not include body weight and the results are normalized to 1.73 m² body surface area, which is an accepted average adult surface area. In our cohort, eCrCl was estimated by using CKD-EPI and MDRD

Table 1. Summary of the formulas to measure and estimate the creatinine clearance

CrCl (mL/min)	(24-hour urinary creatinine × urinary volume)/serum creatinine
CKD-EPI (mL/min per 1.73 m ²)	$141 \times \min(\text{Scr}/\kappa, 1)^{\alpha} \times \max(\text{Scr}/\kappa, 1)^{-1.209} \times 0.993^{\text{Age}^c} \times 1.018$ (if female) × 1.159 (if African American)
^a CKD-EPI (mL/min)	$141 \times \min(\text{Scr}/\kappa, 1)^{\alpha} \times \max(\text{Scr}/\kappa, 1)^{-1.209} \times 0.993^{\text{Age}^c} \times 1.018$ (if female) × 1.159 (if African American) × (BSA/1.73)
MDRD (mL/min per 1.73 m ²)	$175 \times (\text{SCr})^{-1.154} \times (\text{age})^{-0.203} \times 0.742$ (if female) × 1.212 (if Black)
^a MDRD (mL/min)	$(175 \times (\text{SCr})^{-1.154} \times (\text{age})^{-0.203} \times 0.742$ (if female) × 1.212 (if Black)) × (BSA/1.73)
CG (mL/min)	$((140 - \text{age}) (\text{weight in kg}) / 72 \times \text{serum creatinine}) \times 0.85$ if female

Abbreviations: BSA, body surface area; CrCl, creatinine clearance; CG, Cockcroft–Gault formula; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD: Modification of Diet in Renal Disease; SCr, serum creatinine.

For the CKD-EPI formula: κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.

^aDeindexed eCrCl.

deindexed by calculating the body surface area (BSA) of each patient (mean BSA = 2.31 m²) (Table 1). BSA was calculated by the formula of Dubois and Dubois ($0.0071843 \times \text{total body weight [kg]}^{0.425} \times \text{height [cm]}^{0.725}$) (24). Albumin excretion in 24-hour urine volume was available in 182 patients. Publication of the study was approved by the Ethics Committee (CEAVNO—Comitato Etico Area Vasta NordOvest) and, in accordance with the policy of the University Hospital, all patients signed provided informed consent to use their clinical data for scientific research.

An independent study group of 50 healthy individuals without obesity (BMI < 30 kg/m², mean BMI = 23.9 kg/m²) recruited at the nephrology unit as donors for kidney transplantation was used for comparison.

Statistical Analysis

Statistical analyses were performed using SAS software (SAS 9.3, Enterprise guide version 5.1; SAS Institute, Cary, NC). Data are expressed as mean ± SD or mean with 95% CI. The Shapiro–Wilk test was used to assess the normal distribution of the data. Albuminuria over 24 hours were log10 transformed to meet the assumptions of linear regression (ie, homoscedasticity and normal distribution). Associations between normally distributed quantitative variables were assessed by the Pearson’s correlation coefficient. Multivariate regression analysis was used to evaluate the independent determinants of CrCl and albuminuria by including age, sex, body weight, height, presence of diabetes, and hypertension. Unpaired Student’s t-tests were used to evaluate differences according to gender. A paired Student’s t-test was used to compare the measurement of CrCl and the estimation of creatinine clearance calculated with the different formulas with the aim to identify the under or overestimation of the renal function. Nonlinear regression analysis was applied to the mCrCl data to estimate the coefficient on the denominator of the CG formula (ie, 72 in the original CG formula) using the Levenberg–Marquardt algorithm (25, 26). This is an optimization method for nonlinear least-squares problems that combines the steepest descent method and the Gauss–Newton method by introducing a damping

parameter to control the balance between the 2 methods. The CG formula with the new estimated coefficient (= 96 by data fitting) was then modified via linear regression analysis to have a 0 intercept and a unitary slope with respect to mCrCl formula.

A cut-off point for BMI was identified at which the eCrCl calculated using the conventional CG formula was, on average, 7 mL/min higher than the mCrCl. The value of 7 mL/min corresponds to the average difference between the mCrCl and the modified CG equation.

Results

Anthropometric characteristics of the study population are shown in Table 2.

mCrCl was positively associated with body weight ($r = 0.40$, $P \leq .0001$, Fig. 1A) and negatively related to age ($r = -0.40$, $P \leq .0001$, Fig. 1B). In a multivariate analysis including age, gender, height, presence/absence of diabetes, or hypertension, only body weight and age were independent predictors of mCrCl ($\beta = 0.7$ mL/min per 1 kg, $P < .0001$; $\beta = -1.6$ mL/min per 1 year, $P = .0001$, respectively).

In 182 patients in whom 24-hour albuminuria was available, a positive correlation with the mCrCl was observed ($r = 0.17$, $P = .02$). In a multivariate analysis including age,

body weight, height, gender, presence/absence of diabetes, and hypertension, mCrCl ($P = .026$) and diabetes ($P = .03$) were both independent predictors of 24-hour albuminuria.

No significant effects could be demonstrated when systolic and diastolic blood pressure values were added to the multivariate regression analyses.

Comparison Between mCrCl and eCrCl

The results of eCrCl by current formulas are reported in Table 2.

The mCrCl was positively associated with eCrCl by CG ($r = 0.69$, $P < .01$, Fig. 2A), deindexed CKD-EPI ($r = 0.66$, $P < .01$, Fig. 2B), and deindexed MDRD ($r = 0.69$, $P < .01$, Fig. 2C) prediction formulas. In our cohort, the CG formula showed a progressive overestimation at high CrCl values whereas an underestimation resulted from CKD-EPI and MDRD formulas. To further improve the precision of the eCrCl, starting from the CG formula, which includes body weight in its algorithm, we generated a new coefficient (= 96 by data fitting) at the denominator (ie, 72 in the original CG formula). The modified version of the CG formula was then adjusted via linear regression analysis to have a 0 intercept and a unitary slope (Figs. 3 and 4) with respect to the mCrCl as the following:

$$eCrCl = 53 + 0.7 \times \left[\frac{(140 - \text{Age}) \times (\text{Weight})}{96 \times \text{SCr}} \times 0.85 (\text{if female}) \right]$$

where the eCrCl is expressed in mL/min, age in years, body weight in kg, and serum creatinine (SCr) in mg/dL.

To define the cut-off of BMI in terms of appropriateness of the new equation, both the conventional CG equation and our modified CG formula were applied to calculate the eCrCl in an independent study group of 50 healthy individuals without obesity ($\text{BMI} < 30 \text{ kg/m}^2$, mean $\text{BMI} = 23.9 \text{ kg/m}^2$). In this group, we found that our modified formula has a significant proportional bias in predicting mCrCl (slope = 1.77, 95% CI 1.12-2.43, $P = .02$ vs slope = 1), whereas the conventional CG equation does not (slope = 0.93, $P = .69$ vs slope = 1). These results indicate that our modified CG formula is not as accurate as the conventional CG equation for calculation of eCrCl in individuals without obesity. A cut-off of BMI $> 32 \text{ kg/m}^2$ (dotted line, Fig. 5) was then identified as the value above which the conventional CG equation is expected to produce an overestimation of mCrCl, and the new formula may be applied to improve the estimation of CrCl in subjects with obesity.

Discussion

In our population of patients with obesity without primary or overt kidney disease, mCrCl augmented with body weight, with an average increase of 0.7 mL/min per kg. This increase was associated with albumin excretion, suggesting a possible mechanism of early kidney damage.

Although early renal damage may be the consequence of obesity-related comorbidities including diabetes mellitus or hypertension (27), "healthy obesity" without evidence of coexisting cardiometabolic complications is an independent risk factor for renal injury (28, 29), and glomerular hyperfiltration has been identified as a pathogenic link (5). The mechanisms leading to increased glomerular filtration in obesity may recognize an increase in the renal plasma flow and

Table 2. Anthropometric and clinical measures, mCrCl, and eCrCl in the study population

	Men n = 114	Women n = 228	Whole group n = 342
Age (years)	49.0 ± 11.3	49.4 ± 13.1	49.2 ± 12.5
Body weight (kg)	148.5 ± 30.5*	122.5 ± 23.7	131.1 ± 28.8
Height (m)	1.74 ± 0.09*	1.61 ± 0.06	1.65 ± 0.09
BMI (kg/m ²)	48.7 ± 9.5	47.0 ± 8.4	47.6 ± 8.9
BSA (m ²)	2.31 ± 0.27*	2.52 ± 0.26	2.20 ± 0.21
Serum creatinine (mg/dL)	0.9 ± 0.2	0.72 ± 0.16*	0.78 ± 0.19
Urine creatinine (mg/24 hours)	2114 ± 587	1540 ± 470*	1732 ± 579
Urine volume (mL/24 hours)	1769 ± 770	1642 ± 761	1680 ± 764
mCrCl (mL/min)	170 ± 60	154 ± 59*	160 ± 60
eCrCl by CKD-EPI (mL/min per 1.73 m ²)	97 ± 19	97 ± 20	97 ± 19
^a eCrCl by CKD-EPI (mL/min)	143 ± 33	124 ± 30*	130 ± 32
eCrCl by MDRD (mL/min per 1.73 m ²)	96 ± 25	92 ± 27	93 ± 26
^a eCrCl by MDRD (mL/min)	140 ± 40	118 ± 38*	125 ± 40
eCrCl by CG (mL/min)	221 ± 80	195 ± 78*	204 ± 79
eCrCl by new formula (mL/min)	169 ± 42	155 ± 41*	160 ± 42

Data are presented as mean ± SD.

Abbreviations: BMI, body mass index; BSA, body surface area; CG, Cockcroft-Gault; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; eCrCl, estimated creatinine clearance; MDRD, Modification of Diet in Renal Disease; mCrCl, measured creatinine clearance.

* $P < .05$ between males and females as determined by unpaired Student's *t*-test.

^aDeindexed eCrCl was calculated by dividing individual eCrCl by 1.73 and by multiplying the result by the BSA of each patient.




Figure 1. Relationship between body weight, age and mCrCl. Relationship between creatinine clearance and body weight (A) and age (B). In each panel, Pearson's correlation coefficient (r) is reported along with its significance (P).




Figure 2. Relationship between mCrCl and the eCrCl. Relationship between measured creatinine clearance and creatinine clearance estimated by CG (A), CKD-EPI (B), and MDRD (C). Both CKD-EPI and MDRD were deindexed by multiplying the results for BSA/1.73. In each panel, Pearson's correlation coefficient (r) is reported along with its significance (P).

filtration fraction (7). The reduction of preglomerular vascular resistance along with a raise in postglomerular resistance led to an increase in the filtering surface area thus increasing the permeability of the glomerular hydraulic barrier (5). The hemodynamic and the tubular hypotheses have been proposed as possible explanations for this cascade of events. The hemodynamic theory hypothesizes a disequilibrium of vasoactive molecules regulating the tone of afferent and efferent arterioles. The activation of the renin–angiotensin–aldosterone system with increased local production of angiotensin II (8) and activation of endothelin-1 contributes to increase the resistance of efferent arterioles. Additional molecules, such as cyclooxygenase 2 body surface area–derived prostanoids and nitric oxide, have been identified as vasodilatory mediators, leading to a reduction in the afferent arteriolar resistance. The tubular theory hypothesizes that increased sodium reabsorption in the proximal tubule leads to a deactivation of the tubuloglomerular feedback (30), causing a decrease in the afferent arteriole resistance, with consequent increase in the glomerular perfusion and filtration (5).

Important determinants of hyperfiltration include blood pressure, sodium intake, and consumption of meat protein (31). We could not demonstrate a direct effect of blood pressure, extemporarily measured, on both CrCl and albuminuria, which may depend on the heterogeneity of the studied population and on the effect of different antihypertensive drugs. Unfortunately, due to the retrospective nature of the study, we did not have measures of 24-hour urinary sodium and 24-hour urinary urea reflecting sodium and protein intake,

respectively. Prospective studies will be necessary to define the effect size of these determinants on hyperfiltration in subjects with obesity.

Additional mechanisms include the increase in serum leptin that may enhance the sympathetic activity that, in turn, triggers renin–angiotensin–aldosterone system activation and sodium retention in the kidney (5). Changes in production of adiponectin (9) and resistin (32), inflammation (11), oxidative stress (12), abnormal lipid metabolism (33), nephron mass reduction (14), and insulin resistance (34) are further possible mechanisms that may affect the glomerular filtration barrier, with consequent increase in glomerular permeability. The first sign of renal damage is microalbuminuria, suggesting a potential risk of progression to renal failure and the development of premature cardiovascular events, thus worsening the prognosis in patients with obesity (35). Our results show that the mCrCl is independently associated with albuminuria, suggesting a possible mechanism of early kidney damage in patients with obesity. To which extent hyperfiltration, per se, may represent an early sign of renal damage has not been fully clarified yet, and the retrospective nature of our study did not allow us to demonstrate the worsening of kidney damage or a potential progression to kidney failure in our patients. The association of hyperfiltration with elevated urinary albumin excretion has been already described (5). High prevalence of albuminuria was observed in a population of patients with obesity undergoing bariatric surgery (36). In a cross-sectional study of 200 subjects with overweight and obesity, the prevalence of albuminuria was positively associated with BMI (37).




Figure 3. Relationship between mCrCl and CrCl estimated using the new formula. Pearson's correlation coefficient (r) is reported along with its significance (P).




Figure 4. eCrCl using the prediction formulas and mCrCl. (A) Mean difference (\pm SD) between mCrCl and eCrCl by CG (+44.3 mL/min), CKD-EPI (−29.5 mL/min), MDRD (−34.2 mL/min), and the new formula (+0.3 mL/min). * $P < .05$ vs mCrCl as assessed by paired Student's t -test. N.S., not significant. (B) Individual values of mCrCl and eCrCl by CG, CKD-EPI, MDRD, and the new formula. Both CKD-EPI and MDRD formulas were deindexed by multiplying the results for BSA^{1.73}. Abbreviations: CrCl, creatinine clearance; CG, Cockcroft–Gault formula; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; MDRD, Modification of Diet in Renal Disease.

Accordingly, a high prevalence of microalbuminuria (7.1%) or macroalbuminuria (2.7%) has been observed in patients with overweight without diabetes or hypertension (38). In the NHANES 3, subjects with obesity showed higher prevalence of albuminuria in comparison with the general population (39). A decrease in GFR (40), 24-hour creatinine clearance (41), albuminuria, and proteinuria (40, 42) were observed following bariatric surgery. Furthermore, adults with overweight and/or obesity, with no evidence of obesity-related comorbidities, showed increased incidence of initial sign of kidney disease (43). It has been suggested that if hyperfiltration is not promptly treated, the initial glomerulomegaly




Figure 5. Relationship between BMI and CrCl and prediction equations in the cohort of 342 patients with obesity and 50 healthy individuals without obesity. Relationship between mCrCl and BMI in the cohort of 342 patients with obesity (black dots) and in 50 healthy individuals without obesity (red dots). A spline curve fitted to the mCrCl is shown together with the lines predicted by the conventional CG equation and by the modified CG equation. The vertical dotted line indicates a BMI cutoff above which the eCrCl calculated using the conventional CG formula was 7 mL/min higher than the mCrCl. This threshold was chosen because it corresponds to the average difference between the mCrCl measurement and the modified CG equation.

may evolve to glomerulosclerosis (14) and eventually to renal failure (44).

Evaluation of the GFR in patients with obesity may therefore be important, even in the absence of overt kidney disease, to establish whether tailored strategies for weight loss and appropriate pharmacological therapies should be initiated for prevention of the renal damage (45). Several methods including inulin clearance (46), radioisotopic methods, radiocontrast agents, urea, and cystatin C (16) have been used for the evaluation of kidney function. However, these techniques show several disadvantages in the clinical practice due to potentially invasive, time-consuming, and complex or expensive methods of GFR assessment. The creatinine clearance measurement by urine collection over 24 hours represents 1 of the most used techniques, although it results inconvenient due to difficulties for urine collection (16). To encompass these difficulties, prediction equations such as CG (17), MDRD (18), and CKD-EPI (19) have been developed for the estimation of CrCl in the general population. However, these prediction formulas show lack of accuracy in the estimation of GFR in populations without chronic kidney diseases compared with those with the disease (47). Moreover, these formulas have not been validated in patients with obesity, especially when BMI is >40 kg/m², in whom GFR estimation is associated with important biases and inaccuracies (48). Comorbidities such as diabetes and hypertension may also impact on CrCl estimation (49). To minimize the impact of these biases, in our study we excluded patients with primary or overt kidney disease as well as those with mCrCl <60 mL/min, with the aim at identifying patients with hyperfiltration, who may need prompt specific therapeutic measures to slow down the progression of glomerular damage.

In our cohort, the CG formula showed a progressive overestimation at high CrCl values, whereas an underestimation resulted from the CKD-EPI and MDRD formulas. To further

improve the precision of the eCrCl, starting from a CG formula that includes body weight in its algorithm, we generated a new formula for the estimation of CrCl in our population of patients with obesity, with a high correlation coefficient and no deviation at high mCrCl values.

Our study has some limitations. The study population comprised patients of Caucasian ethnicity and it was predominantly composed of women. A proportion of patients were on treatment for diabetes or hypertension, and 24-hour albuminuria was not measured in the whole population. Additionally, due to the retrospective nature of this study, data regarding patients' prognosis were not available. Further studies will be necessary to address this issue.

Conclusion

In patients with obesity without primary or overt kidney damage, the GFR increases with body weight, and it is associated with the presence of albuminuria, suggesting an early kidney damage. We propose a new algorithm for the estimation of CrCl that might be useful in clinical practice to identify a condition of hyperfiltration associated with obesity, with the aim of detecting early glomerular damage and preventing progression of renal disease.

Funding

This study was funded by the Italian Ministry of the University, project code 2017L8Z2EM: Mechanisms of adipose tissue dysfunction in obesity: a target of future weight loss strategies for the prevention of diabetes and cardiovascular diseases.

Author Contributions

A.B. and G.S. interpreted data and wrote the manuscript. D.G., P.P., P.F., and G.C. assisted with the interpretation of the data and revised the manuscript. F.S. and G.S. designed the study protocol. All authors read, critically revised the draft and approved the final manuscript. A.B. has full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Disclosures

The authors declare no conflict of interest.

Data Availability

Some or all datasets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.

Ethics Approval

The study was approved by the local Ethics Committee (CEAVNO—Comitato Etico Area Vasta Nord-Ovest). All procedures performed in this study were in accordance with the ethical standards of the Local Ethics Committee and with the 1964 Helsinki Declaration and its later amendments.

References

1. Ryan D, Barquera S, Barata Cavalcanti O, Ralston J. The global pandemic of overweight and obesity: addressing a twenty-first

- century multifactorial disease. In: Kickbusch I, Ganten D, Moeti M, eds. *Handbook of Global Health*. Springer; 2021:739-773.
2. Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. *N Engl J Med*. 2019;381(25):2440-2450.
3. Hall JE, Henegar JR, Dwyer TM, et al. Is obesity a major cause of chronic kidney disease? *Adv Ren Replace Ther*. 2004;11(1):41-54.
4. Chagnac A, Weinstein T, Korzets A, Ramadan E, Hirsch J, Gafter U. Glomerular hemodynamics in severe obesity. *Am J Physiol Renal Physiol*. 2000;278(5):F817-F822.
5. Cortinovis M, Perico N, Ruggenenti P, Remuzzi A, Remuzzi G. Glomerular hyperfiltration. *Nat Rev Nephrol*. 2022;18(7):435-451.
6. Pruijm M, Wuerzner G, Maillard M, et al. Glomerular hyperfiltration and increased proximal sodium reabsorption in subjects with type 2 diabetes or impaired fasting glucose in a population of the African region. *Nephrol Dial Transplant*. 2010;25(7):2225-2231.
7. Chagnac A, Herman M, Zingerman B, et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption. *Nephrol Dial Transplant*. 2008;23(12):3946-3952.
8. Ruster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. *Semin Nephrol*. 2013;33(1):44-53.
9. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. *Kidney Int*. 2009;76(2):145-148.
10. Shi Z, Li B, Brooks VL. Role of the paraventricular nucleus of the hypothalamus in the sympathoexcitatory effects of leptin. *Hypertension*. 2015;66(5):1034-1041.
11. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. *Eur Cytokine Netw*. 2006;17(1):4-12.
12. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. *J Clin Invest*. 2004;114(12):1752-1761.
13. Palatini P. Glomerular hyperfiltration: a marker of early renal damage in pre-diabetes and pre-hypertension. *Nephrol Dial Transplant*. 2012;27(5):1708-1714.
14. Tsuboi N, Okabayashi Y, Shimizu A, Yokoo T. The renal pathology of obesity. *Kidney Int Rep*. 2017;2(2):251-260.
15. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: an emerging epidemic. *Kidney Int*. 2001;59(4):1498-1509.
16. Traynor J, Mactier R, Geddes CC, Fox JG. How to measure renal function in clinical practice. *BMJ*. 2006;333(7571):733-737.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron*. 1976;16(1):31-41.
18. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med*. 2006;145(4):247-254.
19. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612.
20. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. *J Am Soc Nephrol*. 2005;16(3):763-773.
21. Domislovic M, Domislovic V, Fucek M, et al. Should CKD EPI equation be used for estimation of glomerular filtration rate in obese subjects? *Kidney Blood Press Res*. 2022;47(10): 597-604.
22. Erstad BL, Nix DE. Assessment of kidney function in patients with extreme obesity: A narrative review. *Ann Pharmacother*. 2021;55(1):80-88.
23. Bray GA, Heisel WE, Afshin A, et al. The science of obesity management: an endocrine society scientific statement. *Endocr Rev*. 2018;39(2):79-132.
24. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. *Nutrition*. 1989;5(5):303-311.

25. Levenberg K. A method for the solution of certain non—linear problems in least squares. *Q Appl Math*. 1944;2(2):164-168.
26. Marquardt DW, du Pont EI, Bristol RI, Burrell GC, Marquardt DW. An algorithm for least-squares estimation of nonlinear parameters. *J Soc Indust Appl Math*. 1963;11:431-441.
27. Kosmas CE, Silverio D, Tsimidou C, Salcedo MD, Montan PD, Guzman E. The impact of insulin resistance and chronic kidney disease on inflammation and cardiovascular disease. *Clin Med Insights Endocrinol Diabetes*. 2018;11. doi: [10.1177/1179551418792257](https://doi.org/10.1177/1179551418792257)
28. Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. *Kidney Int*. 2008;73(1):19-33.
29. Kovesdy CP, Furth SL, Zoccali C. Obesity and kidney disease: hidden consequences of the epidemic. *Braz J Med Biol Res*. 2017;50(5):e6075.
30. Schnermann J, Traynor T, Yang T, et al. Tubuloglomerular feedback: new concepts and developments. *Kidney Int Suppl*. 1998;54(67):S40-S45.
31. Hess B. 'Bad dietary habits' and recurrent calcium oxalate nephrolithiasis. *Nephrol Dial Transplant*. 1998;13(4):1033-1038.
32. Ellington AA, Malik AR, Klee GG, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. *Hypertension*. 2007;50(4):708-714.
33. Ruan XZ, Varghese Z, Moorhead JF. An update on the lipid nephrotoxicity hypothesis. *Nat Rev Nephrol*. 2009;5(12):713-721.
34. Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. *Am J Physiol Renal Physiol*. 2016;311(6):F1087-f1108.
35. Praga M, Morales E. Obesity, proteinuria and progression of renal failure. *Curr Opin Nephrol Hypertens*. 2006;15(5):481-486.
36. Rosenstock JL, Pommier M, Stoffels G, Patel S, Michelis MF. Prevalence of proteinuria and albuminuria in an obese population and associated risk factors. *Front Med (Lausanne)*. 2018;5:122.
37. Hemayati R, Kaseb F, Ghadiri-anari A, Yosefi F. The relationship between microalbuminuria, overweight and obesity. *J Nephropathol*. 2020;9(4):e41.
38. Basdevant A, Cassuto D, Gibault T, Raison J, Guy-Grand B. Microalbuminuria and body fat distribution in obese subjects. *Int J Obes Relat Metab Disord*. 1994;18(12):806-811.
39. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. *Kidney Int*. 2002;61(6):2165-2175.
40. von Scholten BJ, Persson F, Svane MS, Hansen TW, Madsbad S, Rossing P. Effect of large weight reductions on measured and estimated kidney function. *BMC Nephrol*. 2017;18(1):52.
41. Navarro-Díaz M, Serra A, Romero R, et al. Effect of drastic weight loss after bariatric surgery on renal parameters in extremely obese patients: long-term follow-up. *J Am Soc Nephrol*. 2006;17(12 Suppl 3):S213-S217.
42. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafer U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. *J Am Soc Nephrol*. 2003;14(6):1480-1486.
43. Chang Y, Ryu S, Choi Y, et al. Metabolically healthy obesity and development of chronic kidney disease: a cohort study. *Ann Intern Med*. 2016;164(5):305-312.
44. Herrington WG, Smith M, Bankhead C, et al. Body-mass index and risk of advanced chronic kidney disease: prospective analyses from a primary care cohort of 1.4 million adults in England. *PLoS One*. 2017;12(3):e0173515.
45. Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *Blood Press*. 2018;27(6):314-340.
46. Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney disease. *Pediatr Nephrol*. 2007;22(11):1839-1848.
47. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function—measured and estimated glomerular filtration rate. *N Engl J Med*. 2006;354(23):2473-2483.
48. Guebre-Egziabher F, Brunelle C, Thomas J, et al. Estimated glomerular filtration rate bias in participants with severe obesity regardless of deindexation. *Obesity (Silver Spring)*. 2019;27(12):2011-2017.
49. Tonneijck L, Muskiet MH, Smits MM, et al. Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment. *J Am Soc Nephrol*. 2017;28(4):1023-1039.